Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up.
OBJECTIVE
The evidence base for fasting plasma glucose (FPG) in the non-diabetic range as a risk factor for cardiovascular disease (CVD) is inconclusive. We investigated this question in the West of Scotland Coronary Prevention Study (WOSCOPS).


RESULTS
In WOSCOPS, we related FPG in 6447 men (mean age 55 years) with hypercholesterolaemia, but no history of CVD or diabetes, to the risk of cardiovascular events and mortality over 14.7 years of follow-up; 2381 non-fatal/fatal cardiovascular events and 1244 deaths occurred. Participants were divided into fifths of baseline FPG, Q1 (< or =4.3 mmol/L) to Q5 (>5.1-6.9 mmol/L). Q2 was designated the referent based on previous studies which have suggested a J-shaped relationship between FPG and CVD. Compared with Q2 (>4.3-4.6 mmol/L), men in Q5 had no elevated risk for cardiovascular events [hazard ratio (HR) 0.95 (0.83-1.08)], or all-cause mortality [HR 0.96 (0.80-1.15)] in fully adjusted analyses despite a significant risk for incident diabetes [HR 22.05 (10.75-45.22)]. After further dividing Q5 into fifths, Q5a-e, individuals in Q5e (FPG 5.8-6.9 mmol/L) were also not at increased risk of cardiovascular events [HR 1.05 (0.82-1.35)] or other endpoints compared with Q2. All results were similar using Q1 as the referent.


CONCLUSIONS
Elevations in FPG in the non-diabetic range were not associated with long-term risk of cardiovascular events in middle-aged men in WOSCOPS. These data suggest that the current FPG cutoff for diagnosing diabetes also appropriately identifies western men at risk of CVD.
Preiss
David
D
Faculty of Medicine, University of Glasgow, Glasgow, UK. d.preiss@clinmed.gla.ac.uk
Welsh
Paul
P
Murray
Heather M
HM
Shepherd
James
J
Packard
Chris
C
Macfarlane
Peter
P
Cobbe
Stuart
S
Ford
Ian
I
Sattar
Naveed
N
D001786:Blood Glucose / Q000378:metabolism*; D003327:Coronary Disease / Q000401:mortality; D003925:Diabetic Angiopathies / Q000097:blood / Q000401:mortality*; D005215:Fasting / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012606:Scotland / Q000453:epidemiology
D001786:Blood Glucose
Lancet. 2006 Jul 1;368(9529):29-36
16815377
N Engl J Med. 2007 Oct 11;357(15):1477-86
17928595
Curr Atheroscler Rep. 2007 Dec;9(6):479-85
18377788
Prim Care Diabetes. 2007 Jun;1(2):69-74
18632022
Lancet. 1999 Aug 21;354(9179):617-21
10466661
Circ Res. 2000 Sep 29;87(7):574-80
11009562
Diabetologia. 2009 Mar;52(3):415-24
19130039
Lancet. 2009 May 23;373(9677):1765-72
19465231
PLoS Med. 2007 Aug;4(8):e263
17760500
JAMA. 2001 May 16;285(19):2486-97
11368702
Diabetes Care. 2003 Nov;26(11):3160-7
14578255
J Am Coll Cardiol. 2008 Jan 22;51(3):264-70
18206734
J Clin Epidemiol. 1995 Dec;48(12):1441-52
8543958
Diabetes Care. 2004 Dec;27(12):2836-42
15562194
Arch Intern Med. 2004 Oct 25;164(19):2147-55
15505129
Diabetes Res Clin Pract. 2009 Feb;83(2):e47-50
19117630
Diabetes Res Clin Pract. 2007 Dec;78(3):305-12
17601626
Circulation. 2009 Feb 17;119(6):812-9
19188510
Arch Intern Med. 2008 Jun 9;168(11):1209-16
18541829
Diabetes Care. 2003 Mar;26(3):688-96
12610023
N Engl J Med. 1995 Nov 16;333(20):1301-7
7566020
Am Heart J. 2007 Apr;153(4):552-8
17383293